Sigurdur (Siggi) Olafsson is the President and Chief Executive Officer at Mallinckrodt Pharmaceuticals. Mr. Olafsson is responsible for providing strategic, financial and operational leadership for the Company and closely coordinating and working with the Board of Directors and the executive committee. Mr. Olafsson is also a member of Mallinckrodt’s executive committee and Mallinckrodt’s Board of Directors.
Mr. Olafsson has almost 30 years of diverse pharmaceutical experience across branded and generic drugs.
Before joining Mallinckrodt, Mr. Olafsson served as CEO of Hikma Pharmaceuticals. Prior to Hikma, Mr. Olafsson served as President and Chief Executive Officer of the Global Generic Medicines Group of Teva Pharmaceuticals. Previously, he was President of Actavis plc (Watson) and CEO of the Actavis Group, which develop, manufacture and distribute branded, generic and biosimilar products. Mr. Olafsson has also held a number of leadership positions in Pfizer’s Global R&D organization in the UK and U.S., focused on branded drug development, and served as Head of Drug Development for Omega Farma in Iceland.
Mr. Olafsson holds a M.S. in pharmacy (Cand Pharm) from the University of Iceland, Reykjavik.